IGARASHI Yuki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Division of Pharmacodynamics (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor

E-mail Address

E-mail address

Page Top ▲

Profile Summary 【 Display / hide 】

  • 　

Page Top ▲

Career 【 Display / hide 】

  • 2023.04
    -
    2025.03

    Yokohama General Hospital, Pharmacy department, pharmacist

  • 2025.04
    -
    Present

    Keio University Faculty of Pharmacy, Division of Pharmacodynamics, Assistant Professor

Page Top ▲

Academic Background 【 Display / hide 】

  • 2012.04
    -
    2019.03

    Keio University, Faculty of Pharmacy, Pharmaceutical department

    University, Graduated

  • 2019.04
    -
    2023.03

    Keio university graduate school

    Graduate School, Graduated, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • Ph.D. in Pharmaceutical Science, Keio university graduate school, Coursework, 2023.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • Pharmacist License, 2019.05

Page Top ▲
 

Papers 【 Display / hide 】

  • Efficacy and Safety of Isavuconazole for Invasive Fungal Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ayano Kawasaki, Ryuya Shintani, Risa Takao, Yuka Nakazawa, Takayuki Mihara, Shintaro Ikegami, Sora Shimada, Yuri Matsumoto, Yuko Okamoto, Yuki Igarashi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto

    Medical Mycology (Oxford University Press)   2025.09

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted

  • Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility

    Maiko Yoshikawa, Tomoyasu Nishimura, Kana Misawa, Rina Shimamura, Kenta Suzuki, Shoko Kashimura, Yuki Igarashi, Yuki Enoki , Kazuaki Taguchi, Naoki Hasegawa, Ho Namkoong, Kazuaki Matsumoto

    Microbiology Spectrum    e0201225 2025.09

    Research paper (scientific journal), Joint Work, Accepted

  • External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study.

    Tomoyuki Ishigo, Ayako Suzuki, Yuta Ibe, Satoshi Fujii, Masahide Fukudo, Hiroaki Yoshida, Hiroaki Tanaka, Hisato Fujihara, Fumihiro Yamaguchi, Fumiya Ebihara, Takumi Maruyama, Yusuke Yagi, Yukihiro Hamada, Masaru Samura, Fumio Nagumo, Toshiaki Komatsu, Atsushi Tomizawa, Akitoshi Takuma, Hiroaki Chiba, Yoshifumi Nishi, Yuki Igarashi, Yuki Enoki, Kazuaki Matsumoto

    Journal of Infection and Chemotherapy 31 ( 5 )  2025.05

    Accepted,  ISSN  1341321X

    　View Summary

    During therapeutic drug monitoring (TDM) for vancomycin (VCM), the area under the concentration-time curve (AUC) is important for balancing efficacy versus toxicity. In a previous study, we developed a decision tree (DT) model to achieve the target AUC during TDM over the follow-up period (AUCfollow-up). This study aimed to validate the DT model for achieving the target AUCfollow-up. Patients who received VCM for at least 72 h and had an initial TDM within four doses between January 2023 and December 2023 were analyzed. The AUC of the initial TDM was calculated over 2-point (peak/trough) concentrations via Bayesian estimation. The target AUCfollow-up was defined as 400–600 μg h/mL. Among 188 patients (median age [interquartile range], 66 [56, 79] years; 50 % female), the target AUCfollow-up was achieved in 70 % (132/188). When the predicted AUC was 400–600 μg h/mL, 84 % (102/121) achieved the target AUCfollow-up. In a 12 h dosing interval subgroup, 86 % (88/102) achieved the target AUCfollow-up. Conversely, when the predicted AUC was <400 or >600 μg h/mL, the proportion who achieved the target AUCfollow-up dropped to 44 % (30/67). Only 30 % (3/10) of those with creatinine clearance rates of >130 mL/min/1.73 m2 achieved the target. The area under the receiver operating characteristics curve was 0.74, and the R2 value was 0.15. Our findings confirmed the external validity of the DT model and supported its use for optimizing VCM dosing. Overall, the DT model offers a reliable framework for achieving target AUC values during follow-up for TDM, aiding safe and effective treatment.

  • Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system

    Takada K., Enoki Y., Samura M., Igarashi Y., Taguchi K., Tanikawa K., Matsumoto K.

    Expert Opinion on Drug Safety  2025.04

    Research paper (scientific journal), Accepted,  ISSN  14740338

    　View Summary

    Background: Metronidazole (MNZ) can be administered for various infections. The impact of comorbidities/concomitant drugs on MNZ-induced central nervous system (CNS) disorders remains unclear. Research design and methods: We assessed the risk of metronidazole-related CNS disorders using the Japan Adverse Drug Event Report (JADER, May 2023) and the US Food and Drug Administration Adverse Event Reporting System (FAERS, Q1 2023), excluding comorbidities/concomitant drugs. Clonazepam and diazepam were evaluated as potential prophylactics based on the efficacy of benzodiazepines for MNZ-related CNS disorders. Reporting odds ratios (ROR) and 95% confidence intervals (CI) were calculated. Additionally, sensitivity analysis by sex and age was conducted. Results: The ROR (95% CI) of CNS disorders associated with MNZ in JADER and FAERS were 3.16 (2.69–3.72) and 1.69 (1.64–1.73), respectively. MNZ was significantly related to CNS disorders after excluding comorbidities (brain/spinal cord or liver abscesses) and concomitant drugs (glucocorticoids, antiepileptic, antiparkinson, and schizophrenia drugs). In sensitivity analysis, MNZ was significantly related to CNS disorders, despite sex and age. The ROR in the concomitant with clonazepam (CZP) was 0.70 (0.53–0.92) in FAERS. Conclusion: MNZ may be associated with CNS disorders, even if comorbidities/concomitant drugs that are potential risk factors for CNS disorders are excluded. Additionally, CZP may suppress CNS disorders.

  • Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age

    Takada K., Samura M., Igarashi Y., Suzuki A., Ishigo T., Fujii S., Ibe Y., Yoshida H., Tanaka H., Ebihara F., Maruyama T., Hamada Y., Komatsu T., Tomizawa A., Takuma A., Chiba H., Yagi Y., Nishi Y., Enoki Y., Taguchi K., Tanikawa K., Kunishima H., Matsumoto K.

    Journal of Pharmaceutical Health Care and Sciences 11 ( 1 )  2025.03

    Accepted

    　View Summary

    Background: Population pharmacokinetic (PPK) models of vancomycin (VCM) commonly use creatinine clearance (CLcr) as a covariate for clearance (CL). However, relying on CLcr in patients of advanced age may lead to inaccuracies in estimating VCM clearance. Therefore, this study aimed to develop and validate a new PPK model specifically for patients aged 75 years and older. Methods: PPK analysis was performed based on the blood concentrations of VCM (n = 159 patients). The predictive performance of the developed model was compared with that of previous models using mean absolute error (MAE) and mean squared error (MSE) for another dataset. Results: The PPK analysis optimized a two-compartment model using CLcr and the Alb levels as covariates at the central compartment of VCM clearance. The final model was as follows: CL (L/h) = 1.96 × (CLcr/3.09) 0.63 × (Serum albumin (Alb) /2.3) 0.22 × exponential (0.11). Clearance between the central and peripheral compartments (L/h) = 4.86. Central compartment volume of distribution (L) = 31.78. Peripheral compartment volume of distribution (L) = 53.64. The validation study revealed that compared with those of previous models (ranging from 0.67 to 0.79 L/h and from 0.81 to 1.11 (L/h)2, respectively), the final model demonstrated the smallest MAE of 0.60 L/h and MSE of 0.65 (L/h)2 for patients of advanced age with serum creatinine levels of < 0.6 mg/dL. Conclusion: The PPK model of VCM for patients of advanced age was optimized by adding the Alb levels and CLcr as covariates for CL. The predictive accuracy of the PPK model for patients with an SCr of < 0.6 mg/dL tended to be higher than those of previous models based just on CLcr. Thus, dosage is suggested to be adjusted based on CLcr and Alb levels for patients with an SCr of < 0.6 mg/dL.

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 炎症性腸疾患・Clostridioides difficile感染症マウスモデルを用いたfidaxomicinの有用性評価

    三原 貴之, 五十嵐 裕貴, 榎木 裕紀, 田口 和明, 松元 一明

    第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会 , 

    2025.09
    , 

    Oral presentation (general)

  • 造血器腫瘍患者におけるバンコマイシン薬物動態モデル別の予測性の検討

    坂本靖宜, 重村明香, 井出和男, 渡邉直優, 鈴木智代, 五十嵐裕貴, 榎木裕紀, 加藤英明, 松元一明

    第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会 , 

    2025.09
    , 

    Oral presentation (general)

  • 2点採血でバンコマイシンのAUCを算出した症例におけるAKIリスクの層別化

    石郷友之, 鈴木絢子, 藤居賢, 伊部裕太, 吉田博昭, 田中宏明, 海老原文哉, 丸山拓実, 八木祐助, 佐村優, 南雲史雄, 小松敏彰, 冨澤淳, 詫間章俊, 千葉博暁, 五十嵐裕貴, 榎木裕紀, 浜田幸宏, 西圭史, 松元一明

    第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会 , 

    2025.09
    , 

    Oral presentation (general)

  • Mycobacterium avium complexに対するβラクタム系抗菌薬2剤併用のin vitroにおける有効性評価

    吉川万衣子, 西村知泰, 三澤可奈, 島村莉奈, 鈴木健太, 五十嵐裕貴, 榎木裕紀, 長谷川直樹, 南宮湖, 松元一明

    第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会 , 

    2025.09
    , 

    Oral presentation (general)

  • Hollow Fiber Infection Modelを用いた肺MAC症に対する標準治療の有効性評価

    鈴木健太, 島村莉奈, 吉川万衣子, 宇山杏奈, 林侑孝, 五十嵐裕貴, 榎木裕紀, 西村知泰, 松元一明

    第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会, 

    2025.09
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 瞬間的MICとHFIMを用いた感染部位指向型PK/PD評価手法の構築

    2025.04
    -
    2027.03

    Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Scientific Research, Grant-in-Aid for Research Activity Start-up, Principal investigator

  • MA-T技術を活用した新規消毒剤の開発研究

    2025
    -
    2026.03

    OTC Self-Medication Promotion Foundation, 調査・研究助成, Principal investigator

Page Top ▲

Awards 【 Display / hide 】

  • 第8回フレッシャーズ・カンファランス優秀演題発表賞

    島村莉奈,西村知泰,吉川万衣子,三澤可奈,矢野大和,榎木裕紀,五十嵐裕貴,長谷川直樹,南宮湖,松元一明, 2025.06, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態変化

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本化学療法学会Young Challenger Award（YCA）2025

    五十嵐裕貴, 2025.05, 日本化学療法学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第34回日本医療薬学会年会Postdoctoral award

    五十嵐裕貴, 2024.11, 日本医療薬学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 2023年度KP会星野尚美記念薬学研究・活動奨励賞 研究論文部門

    五十嵐裕貴, 2024, Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

    Type of Award： Other

  • Sato Pharmaceutical Research Encouragement Award

    五十嵐裕貴, 2020, 佐藤製薬株式会社, PK/PD理論に基づくCefditorenの適正使用を目指したマウスにおける薬物動態研究

    Type of Award： Other

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2025

  • SEMINAR (PHARMACODYNAMICS)

    2025

  • RESEARCH FOR BACHELOR'S THESIS 1

    2025

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2025

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2025

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • The Japanese Society of Clinical Pharmacology and Therapeutics, 

    2025.01
    -
    Present

  • The Japanese Society of Pharmaceutical Health Care and Sciences, 

    2021.02
    -
    Present

  • Japanese Society of Chemotherapy, 

    2019.11
    -
    Present
Page Top ▲